The UK’s three pharma giants GlaxoSmithKline, Shire and AstraZeneca have not given investors much cause for celebration in recent months and the outlook isn’t particularly encouraging, says Megan Boxall. Click here to read the latest on a sector in need of a tonic.
In this week's portfolio clinic, our experts reckon our reader's portfolio is quite high risk, so he should consider some safer assets. Click here to read what Chris Dillow and our guest experts suggest.
Elsewhere and after going to press this week, we had a flurry of company news with U+I proving its doubters wrong, plus the latest from Morses Club, Phoenix Spree Deutschland and ULS Technology. There was also an exclusive on Polymetal from Alex Newman, as the Russian company's CEO may soon push for a long-term move into rare earth minerals.
